TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04557449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: CDK4 inhibitor

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Endocrine Therapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Endocrine Therapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Endocrine Therapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Endocrine Therapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Endocrine Therapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Endocrine Therapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Endocrine Therapy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Endocrine Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Benzodiazepine used for DDI

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Androgen Receptor inhibitor

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Androgen Receptor inhibitor
Study: NCT04095390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400 mg
Study: NCT03092453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mature dendritic cell (DC) vaccine
Description: Mature DC 7.5-15 million/peptide followed by 2 booster every six weeks of 1-5 million/peptide followed by standard of care anti PD-1 therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 300mg/m^2
Description: administered prior to subject's first DC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: administered 7-8 weeks after subject's last DC dose
Study: NCT00878072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir
Description: Famciclovir 1500 mg (3 x 500 mg tablets) oral as a single dose.
Study: NCT04095390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: 125mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: 125mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: 125mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 500mg
Study: NCT03047044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimizing basal infusion (B.I)
Description: In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: \~ 8 hr: 2 - 4 ml, 8-24 hr: 1 - 3 ml, 24 hours \~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 4 ml (or 0.5 ml).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PCA mode
Description: Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes
Study: NCT04008069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Sarilumab 200 mg administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Sarilumab 200 mg administered subcutaneously
Study: NCT02625337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood taking
Description: Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.
Study: NCT04008069

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study: NCT02625337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood taking
Description: Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood taking
Description: Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.
Study: NCT00191646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2, Intravenously (IV), day 1 and day 8 every (q) 21 days x 6 cycles~If anything other than complete response in Paclitaxel arm patients, 1000 mg/m\^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity
Study: NCT02488109

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher Calorie Refeeding

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Calorie Refeeding
Study: NCT01738217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluobeam
Study: NCT04394130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2%
Description: continuous peripheral nerve local anesthetic infusion (ropivacaïne 0.2 %) for 48 hours postoperative.
Study: NCT02336906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol 3350
Description: Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and the stepped down to 0.8gr/kg subsequently tapered according to stool consistency and frequency.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constipation behavioral therapy
Description: Patients in the active group will receive dietary instruction as to fiber content, as well as behavior therapy including active sitting on the toilet to attempt defacation following meals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Urotherapy
Description: The children will be guided for appropriate drinking and toilet habits, and will start with timed voiding.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Urotherapy
Description: The children will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
Study: NCT01524016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE
Description: Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. Tracer doses of 68Ga-DOTATATE will be used to image tumors by Positron Emission Tomography / computed tomography (PET/CT)
Study: NCT01788709

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preparation cleaning solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preparation cleaning solution
Study: NCT05040139

Intervention type: PROCEDURE
Intervention: Malone Procedure
Description: Surgical procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, the procedure is performed under general anesthesia. The surgeon bring the end of the appendix (or a tubulized segment of the ileum) out through the abdominal wall. The appendix is opened and sutured to the abdominal skin.

Intervention type: PROCEDURE
Intervention: Percutaneous endoscopic caecostomy
Description: Endoscopic procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, a coloscopy is performed to reach the caecum. The cutaneous location of the caecostomy is determined by transillumination of the caecum. A caecopexy is performed with 3 anchors at the chosen location. A specific pig-tail catheter (Chait catheter) is placed percutaneously into the caecum in the center of the 3 anchors.
Study: NCT03974893

Intervention type: OTHER
Intervention: Vegetarian Diet
Description: Dietary information will be collected utilizing a food record at four time points in therapy reflecting different intensities/drug exposures of treatment.
Study: NCT03065231

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extraventricular Drain
Description: As mentioned above, intervention will take place to promote subarachnoid blood diversion from cerebrospinal fluid after ruptured intracranial aneurysm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Drain
Study: NCT06504121

Intervention type: DEVICE
Intervention: Septal Occluder Device
Description: Transcatheter PFO closure with any commercially available septal occluder device
Study: NCT00721916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)
Description: L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
Study: NCT00191646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2, IV, Day 1, q 21 days x 6 cycles~If complete response both Paclitaxel and Gemcitabine arms may elect to receive consolidation therapy, 135 mg/m\^2, IV, 3 hours q 28 days x 12 cycles (1 year)~If no complete response, then Gemcitabine arm patients may receive 175 mg/m\^2, IV, Day 1, q 21 days until complete response, disease progression or unacceptable toxicity
Study: NCT00721916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)
Description: L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle l-LV 200 mg/m2 iv. for 2 hr on day 1 5-FU 400 mg/m2 bolus on day 1 5-FU 2400 mg/m2 ci for 46 hr (day 1, 2hr～48hr)
Study: NCT01360437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel 10mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 90mg twice a day
Study: NCT03755180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: In exercise training, aerobic exercise and strengthening exercises, especially for gastrocnemius and tibialis anterior muscles, will be applied to the patients. In addition the exercise training, Compression Therapy is applied to patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression Therapy
Description: Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression Therapy
Description: Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
Study: NCT04348955

Intervention type: BEHAVIORAL
Intervention: Women between 18 and 70 years old with an adjuvant breast cancer histologically characterized
Description: Quality of life and anxiety questionnaires before the course of chemotherapy (C1 and C4).~Touch-Massage during the course of chemotherapy (from C1 to C3) Anxiety questionnaire at the end of the course of chemotherapy (from C1 to C3)
Study: NCT03258996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified vestibular incision subperiosteal tunnel access
Description: Single vertical mucosal incision, in the middel of the area to be treated, from which we began to lift a mucoperiosteal flap in a single plane.~With a micro-scalpel intrasulcular incisions are made extending to the base of the papillas.~Preparation of a tunnel in the same plane. Take a connective tissue graft on the same side of the palate. The connective graft is inserted through the vertical incision prepared with the aid of the suture.~All is stabilized by means of suspensory sutures of coronal traction on each point of contact.~Finally the vertical incision made is sutured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally advanced flap
Description: Oblique submarginal incisions in both interdental areas of each recession, which continue with the intrasulcular incision, one tooth extending on each side of the teeth to be treated.~A partial-total-partial thickness flap is elevated in the coronal-apical direction.~A vestibular mucosal dissection is performed to eliminate muscle tension. The remnant tissue of the anatomical interdental papillas is desepithelized. Take a CTG on the same side of the palate. The connective tissue graft is stabilized with resorbable suture over the recessions with suspensory sutures on the teeth.~Finally, suspensory sutures with non-resorbable sutures are also used to achieve an accurate adaptation of the vestibular flap over the exposed root and stabilize each surgical papilla over each desepithelized interdental area.
Study: NCT03493633

Intervention type: DEVICE
Intervention: EzyGain
Description: Each patient performs a minimum of 3 sessions per week with the investigator / APA investigator, for 4 weeks, each walk for a few minutes (\<60 min).~Evaluation of the spontaneous physical activity of the patient by actimetry for seven days QAPPA (questionnaire of physical activity for elderly person) a week and a month after the training phase of four weeks
Study: NCT01909115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1000 IU of Vitamin D3
Description: 1000 IU of Vitamin D will be administered in capsule form, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4000 IU of Vitamin D3
Description: 4000 IU of Vitamin D will be administered in capsule form, once daily.
Study: NCT04021160

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency repetitive transcranial magnetic stimulation (rTMS)
Description: 10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: A sham coil will be used that is shielded so that it produces sounds and sensations similar to the active coil but does not produce therapeutic effects. 10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
Study: NCT02202057

Intervention type: OTHER
Intervention: Respiratory resistive load on inhalation
Description: The participant will be seated in a chair, and will be instructed to relax and breathe through a facemask. Five respiratory resistive loads (5-40 cmH2O resistive pressure) will be applied between 3-5 times during inhalation. Following each loaded breath, participants will rate the perceived difficulty of breathing in.

Intervention type: OTHER
Intervention: Respiratory resistive load on inhalation
Description: The participant will be seated in a chair, and will be instructed to relax and breathe through a facemask. Five respiratory resistive loads (5-40 cmH2O resistive pressure) will be applied between 3-5 times during inhalation. Following each loaded breath, participants will rate the perceived difficulty of breathing in.

Intervention type: OTHER
Intervention: Fluoroscopic swallowing evaluation
Description: Participants with PD only will receive a swallowing evaluation as part of their routine clinical care. Generally, the standard clinical evaluation protocol consists of multiple swallows of thin liquid barium, pudding-thick barium, and a cracker or cookie coated with barium. Results are reviewed by the treatment speech-language pathologist, and for the purposes of this study, the researchers will review the most recently recorded swallow study and identify the worst observed penetration-aspiration (PA) score.
Study: NCT03166904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistusertib(AZD2014)
Description: Vistusertib(AZD2014) is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
Study: NCT00191646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles~Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles~Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles
Study: NCT00810381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: intravenous infusion; 0, 0.125, 0.25, 0.5, 1 and 2 µg/kg/min; 20 minutes per infusion step

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide-Dinitrate
Description: intravenous infusion; 0, 0.5, 1, 2, 4, and 6 µg/kg/min; 20 minutes per infusion step

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium-nitroprusside
Description: intravenous infusion; 0, 0.25, 0.5, 1, 2, and 4 µg/kg/min; 20 minutes per infusion step

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline solution (control substance)
Description: intravenous infusion, infusion period 120 minutes
Study: NCT01739673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultraviolet-A and riboflavin
Study: NCT03139097

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study: NCT03599921

Intervention type: BEHAVIORAL
Intervention: Family-based treatment
Description: Family-based treatment, or FBT, is the leading evidenced based therapy for children and adolescents with an eating disorder.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore the patient's weight, then hand control of eating back to the patient as is age appropriate. Toward the end of treatment, it is concerned with developmental issues that may have been impacted by the illness.

Intervention type: BEHAVIORAL
Intervention: Enhanced Cognitive behavioral therapy
Description: Enhanced Cognitive behavioral therapy, or CBT-E, is a leading evidence based treatment for adolescents and adults with an eating disorder.~The treatment is a one-to-one talking type of treatment that primarily focuses on what is keeping the eating problem going. It is therefore mainly concerned with the present and the future. It addresses the origins of the problem as needed.

Intervention type: BEHAVIORAL
Intervention: Family-based treatment modified for ARFID
Description: Family-based treatment modified for individuals with an ARFID diagnosis is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore patient's weight and variety in eating, as needed.

Intervention type: BEHAVIORAL
Intervention: FBT + UP for ARFID
Description: Family-based treatment combined with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and begins with focus on psychoeducation, family engagement, and weight gain as needed. The Unified Protocol is then added to build skills that empower the patient to cope with difficult emotions, address avoidance, and increase tolerance of emotions or disgust responses.
Study: NCT00870935

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon catheter
Description: Hysterosalpingography is performed using intrauterine balloon catheter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon catheter
Description: Hysterosalpingography is performed using intrauterine balloon catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical vacuum cup
Description: Hysterosalpingography is performed using cervical vacuum cup

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical vacuum cup
Description: Hysterosalpingography is performed using cervical vacuum cup
Study: NCT00714051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fall prevention training
Description: Training on a specialized treadmill that produced trip-simulating perturbations (movements.
Study: NCT04318327

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHE885
Description: Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHE885
Description: Infusion
Study: NCT00714051

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants walked on a treadmill at a self-selected speed once per week for four weeks.
Study: NCT02992548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Study: NCT00105157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0518
Description: MK0518 oral tablets 200 mg b.i.d, for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0518
Description: MK0518 oral tablets 400 mg b.i.d, for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0518
Description: MK0518 oral tablets 600 mg b.i.d, for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to MK0518, oral tablet b.i.d, for 24 weeks
Study: NCT00967395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healing
Description: Healing in our study is given be a healer no-touch, who just has to be present in the room.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham healing
Description: Sham Healing in our study is given be a student no-touch, who just has to be present in the room.